After a brush with the kind of last-minute uncertainty over which bankers lose sleep, biotech’s big week on Wall Street paid dividends — and some investors are worried the sector is taking a turn for the absurd.

Five biotech startups went public this week, and each one saw its share price rise in early trading. Armo Biosciences (ARMO), at work on cancer immunotherapy, jumped more than 50 percent minutes after its debut. The dermatology-focused Menlo Therapeutics (MNLO) rose 66 percent once investors got a chance to bid on shares, and ResTORbio (TORC), at work on a treatment for respiratory tract infections, went up 30 percent. Eyenovia (EYEN), a company focused on ophthalmology, went up by about 8 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy